drugset / Trial / NCT00819247

The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer

NCT00819247

Phase 2 Completed 129 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial was to select a dose of degarelix (FE 200486). Three groups of patients were treated for six months on different doses. The patients had blood samples taken and measured for Testosterone in order to determine the most efficient dose to provide fast and sustained castration. The patients came to the clinic for 16 visits and dependent on the blood sample results they were invited to return for additional blood samples on a two weekly basis.

Timeline

Start
2001-03
Primary completion
2002-05
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified 20 mg Subcutaneous
Subject Degarelix Other / unclassified 40 mg Subcutaneous

Indications